Onconic "Confirms Potential to Reduce Muscle Loss from Obesity Treatments"
OCN-501 Combination Study Presented at U.S. Obesity Conference
Weight Loss: 13.1% vs. 15.3%, with No Significant Difference
Improvements in Muscle Mass and Strength, and Reduction in Adipose Tissue Confirmed
Onconic Therapeutics has confirmed the potential to develop a new drug that can reduce muscle loss during weight loss, a major limitation of obesity treatments.
Onconic Therapeutics announced on Nov. 17 that it had delivered an oral presentation on the results of a preclinical study combining semaglutide with OCN-501, a drug candidate being developed to treat muscle metabolic disorders, at ObesityWeek 2026, the annual scientific meeting of The Obesity Society, held in Washington, D.C., on Nov. 16 (local time).
OCN-501 is an oral small-molecule drug candidate being developed to maintain energy metabolic homeostasis in muscles and ease signals that trigger muscle protein breakdown. In this study, the combination showed weight-loss effects similar to those of semaglutide alone, while also improving muscle mass and strength and further reducing adipose tissue.
The researchers compared a group of mice with high-fat diet (HFD)-induced obesity that received semaglutide alone by subcutaneous injection with a group that received semaglutide by subcutaneous injection in combination with oral OCN-501. Weight loss was 13.1% and 15.3%, respectively. Although the figure was higher in the combination group, the difference was not statistically significant.
Analysis of adipose tissue showed statistically significant reductions in both inguinal white adipose tissue (iWAT), which corresponds to subcutaneous fat, and epididymal white adipose tissue (eWAT), an experimental indicator of visceral fat, in the combination group compared with the semaglutide-only group.
In the semaglutide-only group, the mass of the gastrocnemius, a calf skeletal muscle, decreased along with body weight, while muscle mass improved in the OCN-501 combination group. In particular, the gastrocnemius mass relative to body weight was statistically significantly higher in the combination group.
Grip-strength tests to assess muscle function showed decreased strength in the semaglutide-only group, while the combination group had a significant reduction in the decline in muscle strength. A similar improvement in grip strength was also observed in the combination group after adjusting for body weight.
In addition, the muscle fiber area ratio and mean muscle fiber cross-sectional area (CSA), both of which decreased in the semaglutide-only group, showed improvement in the combination group, approaching levels seen in the normal-diet group.
Onconic Therapeutics plans to leverage the advantages of oral medication to develop OCN-501 as an add-on combination therapy that provides muscle-preserving benefits alongside incretin-based treatments, targeting a market that is expanding as existing treatments grow.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A company representative said, "We expect demand to grow alongside the market, as this is a combination drug that addresses the unmet need of muscle loss associated with incretin-based treatments, which already lead the obesity treatment market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.